Clinical Studies

Clinical studies are critical to help deliver innovative medicines to people with cancer. These studies ensure that an investigational medicine is effective and safe. We are grateful to the patients, healthy volunteers, families, hospitals and clinics that participate in our clinical studies and help make progress possible.

For more information, follow the links below to the study listings on Medical professionals may also email us at for specific questions related to our clinical studies.

Our clinical studies
  • Ripretinib

    DiseasePhaseStudy FocusMore Info
    Advanced GIST previously treated with imatinib with mutations in KIT exon 11 and 17/18Phase 3A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)
    GISTPhase 1 Expansion StudyA Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced


  • Vimseltinib

    Disease Phase Study Focus More Info
    Malignant solid tumors and tenosynovial giant cell tumor (TGCT) Phase 1/2 Study A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
    Tenosynovial giant cell tumor (TGCT) Phase 3 A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)


  • DCC-3116

    DiseasePhaseStudy FocusMore Info
    Advanced or metastatic solid tumorsPhase 1/2A Study of DCC-3116 as a Single Agent and in Combination with Sotorasib and with QINLOCK in Patients with Advanced or Metastatic Solid Tumors.


  • DCC-3084


    DiseasePhaseStudy FocusMore Info
    Advanced or metastatic solid tumors with Class I, II, and III BRAF mutations, BRAF fusions, and BRAF/CRAF heterodimers. Phase 1/2A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway